<DOC>
	<DOCNO>NCT01378429</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , parallel group , safety study effect ciclesonide nasal aerosol ( 74 mcg ) HPA axis administer daily male premenarchal female subject 6 11 year age diagnosis PAR .</brief_summary>
	<brief_title>Safety Study Potential Inhibitory Effects Ciclesonide Nasal Aerosol Hypothalamic-Pituitary-Adrenal Axis Subjects 6-11 Years With Perennial Allergic Rhinitis</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled , parallel group , safety study effect ciclesonide nasal aerosol ( 74 mcg ) HPA axis administer daily male premenarchal female subject 6 11 year age diagnosis PAR . The study require subject domicile two 24- 36-hour time period sample collection serum urinary free cortisol measurement , well PK evaluation ( single [ predose ] time point first domicile period , 24-hour sample second domiciled period ) .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Gives write informed consent ( parent/legal guardian ) assent ( appropriate , child ) , include privacy authorization well adherence concomitant medication withhold period , prior participation . Is male premenarchal female 6 11 year old ≥ 20 kg screen visit . Is general good health ( define absence clinically relevant abnormality determine investigator ) base screen physical examination medical history . Has history PAR relevant perennial allergen ( house dust mite , cockroach , mold , animal dander ) minimum one year immediately precede study screen visit . The PAR must sufficient severity require treatment ( either continuous intermittent ) past require treatment throughout entire study period . Has demonstrate sensitivity least one allergen know induce PAR ( house dust mite , cockroach , mold , animal dander ) base document result standard skinprick test either within one year prior screen visit perform screening visit . A positive test define wheal diameter least 3 mm large negative control wheal skinprick test . The subject 's positive allergen test must consistent medical history PAR , allergen must present subject 's environment throughout study . Has history physical finding nasal pathology , include nasal polyp clinically significant respiratory tract malformation ; recent nasal biopsy ; nasal trauma ; nasal ulcer perforation . Surgery atrophic rhinitis rhinitis medicamentosa permit within 120 day prior screen visit . Has evidence infection , significant anatomic abnormality , ulceration mucosa , blood nose , clinically relevant find nasal examination screen visit . Has nasal jewelry . Has participate investigational drug trial within 30 day precede screen visit planning participation another investigational drug trial time trial . Has know hypersensitivity corticosteroid excipients formulation ciclesonide . Has history respiratory infection disorder , include limited bronchitis , pneumonia , influenza , severe acute respiratory syndrome ( SARS ) , within 14 day precede screen visit . Has history adrenal insufficiency . Has active asthma require treatment inhale systemic corticosteroid and/or routine use betaagonists controller drug ( eg , theophylline , leukotriene antagonist ) ; intermittent use ( ≤ 3 us per week ) inhale shortacting betaagonists acceptable . Use shortacting betaagonists exerciseinduced bronchospasm allow . Is expect use disallow concomitant medication treatment period . Is , investigator 's judgment , seasonal exacerbation time screen visit . Is plan initiation immunotherapy study period dose escalation study period . However , initiation immunotherapy 90 day prior screen visit use stable ( maintenance ) dose ( 30 day ) may consider inclusion . Has nonvaccinated exposure active infection chickenpox measles within 21 day precede screen visit . Initiates pimecrolimus cream 1 % great tacrolimus ointment 0.03 % great study period plan dose escalation study period . However , initiation creams/ointments 30 day prior screen use stable ( maintenance ) dose study period may consider inclusion . Has experience significant blood loss within 60 day loss plasma within 72 hour prior screen visit intend undergo elective surgery within 30 day follow end study . Is child immediate relative clinical investigator site personnel , even directly involve study . Resides household another subject participate study time . Has follow condition judge investigator clinically significant and/or affect subject 's ability participate clinical trial : impaired hepatic function history ocular disturbance , eg , glaucoma posterior subcapsular cataract herpes simplex systemic infection hematological ( include anemia ) , hepatic , renal , endocrine disease gastrointestinal disease malignancy ( exclude basal cell carcinoma ) current neuropsychological condition without drug therapy . Any behavioral condition could affect subject 's ability accurately report symptom caregiver developmental delay , attention deficit disorder , autism . Has condition , judgment investigator , would preclude subject complete protocol capture assessment write .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Perennial Allergic Rhinitis</keyword>
	<keyword>PAR</keyword>
</DOC>